ENMD-2076 L-()-Tartaric acid is primarily utilized in the pharmaceutical industry as an active ingredient in the development of targeted cancer therapies. It functions as a multi-kinase inhibitor, specifically targeting Aurora A, VEGFR, and FLT3 kinases, which play critical roles in tumor growth and angiogenesis. This makes it a promising candidate for treating various cancers, including breast cancer, ovarian cancer, and acute myeloid leukemia. Additionally, its tartaric acid component aids in improving the solubility and stability of the compound, enhancing its bioavailability and efficacy in therapeutic applications. Research and clinical trials continue to explore its potential in combination therapies and its effectiveness in overcoming drug resistance in cancer treatment.